Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Processes 1Neoplastic Processes 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 2Pemetrexed 2nilotinib 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1Zoledronic Acid 1Trastuzumab 1Radiosurgery 1MRX-2843 1Everolimus 1Electrochemotherapy 1Denosumab 1Cisplatin 1Carboplatin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplastic Processes × MRX-2843 × Clear all
NCT03510104 2026-01-08

Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

Meryx, Inc.

Phase 1 Completed
42 enrolled

Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡